Cardinal (CAH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks
05-01

For the quarter ended March 2025, Cardinal Health (CAH) reported revenue of $54.88 billion, down 0.1% over the same period last year. EPS came in at $2.35, compared to $2.08 in the year-ago quarter.

The reported revenue represents a surprise of -0.27% over the Zacks Consensus Estimate of $55.03 billion. With the consensus EPS estimate being $2.15, the EPS surprise was +9.30%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Cardinal performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenue- Pharmaceutical and Specialty Solutions: $50.43 billion versus the four-analyst average estimate of $50.33 billion. The reported number represents a year-over-year change of -0.4%.
  • Revenue- Other: $1.30 billion versus $1.29 billion estimated by four analysts on average.
  • Revenue- Medical Products and Distribution: $3.16 billion versus the four-analyst average estimate of $3.21 billion. The reported number represents a year-over-year change of +1.5%.
  • Segment profit- Pharmaceutical and Specialty Solutions: $662 million versus $635.77 million estimated by four analysts on average.
  • Segment profit- Other: $134 million versus $119.24 million estimated by four analysts on average.
  • Segment profit- Global Medical Products and Distribution: $39 million compared to the $44.16 million average estimate based on four analysts.
View all Key Company Metrics for Cardinal here>>>

Shares of Cardinal have returned +1.9% over the past month versus the Zacks S&P 500 composite's -0.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Cardinal Health, Inc. (CAH) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10